MYOS Appoints Sapna Srivastava as a Senior Advisor

CEDAR KNOLLS, NJ--(Marketwire - Nov 12, 2012) - MYOS Corporation (OTCBB: MYOS), a company focused on the discovery, development and commercialization of therapeutic products that improve muscle health and performance, announced today the appointment of Dr. Sapna Srivastava as a Senior Advisor.

The MYOS corporate leadership team expressed enthusiasm for the addition of Dr. Srivastava to their corps of advisors. "I am thrilled that we now have access to such a talented industry expert and analyst on board at MYOS, and look forward to working with Dr. Srivastava as we expand our business," said Robert J. Hariri, M.D., Ph.D., Acting Chairman. "We are fortunate to have Sapna's combined scientific and financial expertise in this important advisory role," added Peter Levy, Chief Operating Officer of MYOS, "We are confident that her experience in the biotechnology industry will provide invaluable strategic insight for MYOS and enhance our future growth." 

Dr. Srivastava brings with her more than a decade of experience in the biotechnology industry and Wall Street. Most recently, she had been the lead biotechnology industry analyst at Goldman Sachs. Prior to that she was a senior biotechnology analyst at Morgan Stanley and also held similar roles at ThinkEquity Partners and J.P. Morgan. She has been recognized as among the best stock pickers in the industry by Wall Street Journal and Forbes. Dr. Srivastava received her Ph.D. in Neuroscience from New York University School of Medicine and her B.Sc. from St. Xavier's College in India.

"I am very excited to be part of the team in building MYOS," said Ms. Srivastava, "There is a significant unmet medical need in muscle health and I believe MYOS's singular focus, innovative efforts, and world class talent can make a significant impact in addressing this need over the years to come."

About MYOS Corporation

MYOS is a development stage company focused on the discovery, development and commercialization of therapeutic products that improve muscle health and performance. MYOS is the owner of MYO-T12, the world's first clinically demonstrated myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. MYO-T12 is manufactured to optimize biological activity, which MYOS believes has the potential to redefine existing standards of physical health and wellness enhancement. For more information on MYO-T12 and to discover why MYOS is known as "The Muscle Company,"™ visit www.myoscorp.com.

Forward-Looking Statements

Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.